ampelopsin has been researched along with Neoplasm Metastasis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, C; Huang, HC; Huang, YL; Lai, YH; Pan, YL; Wang, CC | 1 |
| Chen, Y; Ding, F; Li, B; Li, S; Liu, P; Liu, T; Sun, X; Wang, F; Wang, S; Yu, N; Zhang, X; Zhao, Y | 1 |
| Liu, DY; Zheng, HQ | 1 |
| Chou, CH; Hsieh, YH; Lin, CW; Lu, KH; Yang, JS; Yang, SF | 1 |
4 other study(ies) available for ampelopsin and Neoplasm Metastasis
| Article | Year |
|---|---|
Ampelopsins A and C Induce Apoptosis and Metastasis through Downregulating AxL, TYRO3, and FYN Expressions in MDA-MB-231 Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Flavonoids; Humans; Neoplasm Metastasis; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fyn; Receptor Protein-Tyrosine Kinases | 2019 |
Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Flavonoids; Humans; I-kappa B Proteins; Neoplasm Metastasis; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Ovarian Neoplasms; Sulfones; Time Factors; Up-Regulation; Vimentin | 2015 |
[Anti-invasive and anti-metastatic effect of ampelopsin on melanoma].
Topics: Animals; Antineoplastic Agents; Cell Movement; Disease Models, Animal; Flavonoids; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Movement; Flavonols; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Osteosarcoma; Sp1 Transcription Factor; Urokinase-Type Plasminogen Activator | 2021 |